checkAd

     165  0 Kommentare Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results - Seite 3

    For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

    For further information, please contact:

    Investors:
    Robert Andrade
    Chief Financial Officer
    Fennec Pharmaceuticals Inc.
    (919) 246-5299

    Lesen Sie auch

    Media:
    Elixir Health Public Relations
    Lindsay Rocco
    (862) 596-1304
    lrocco@elixirhealthpr.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results - Seite 3 ~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) - …